| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 469 | 2025 | 5196 | 25.350 |
Why?
|
| Neoplasm, Residual | 20 | 2024 | 1015 | 3.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 67 | 2024 | 8647 | 3.090 |
Why?
|
| Thalidomide | 50 | 2021 | 886 | 2.670 |
Why?
|
| Boronic Acids | 67 | 2024 | 915 | 2.490 |
Why?
|
| B-Cell Maturation Antigen | 17 | 2024 | 149 | 2.330 |
Why?
|
| Plasma Cells | 23 | 2023 | 599 | 2.310 |
Why?
|
| Pyrazines | 67 | 2024 | 1205 | 2.210 |
Why?
|
| Dexamethasone | 51 | 2024 | 1965 | 2.050 |
Why?
|
| Paraproteinemias | 12 | 2022 | 252 | 2.050 |
Why?
|
| Antineoplastic Agents | 105 | 2024 | 13676 | 2.020 |
Why?
|
| Immunotherapy, Adoptive | 19 | 2024 | 1512 | 1.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 77 | 2024 | 11878 | 1.910 |
Why?
|
| Drug Resistance, Neoplasm | 46 | 2024 | 5341 | 1.900 |
Why?
|
| Cell Line, Tumor | 126 | 2025 | 17140 | 1.850 |
Why?
|
| Neoplasms, Plasma Cell | 5 | 2023 | 38 | 1.730 |
Why?
|
| Syndecan-1 | 11 | 2020 | 163 | 1.730 |
Why?
|
| Mice, SCID | 63 | 2021 | 2627 | 1.610 |
Why?
|
| T-Lymphocytes, Cytotoxic | 12 | 2024 | 1801 | 1.580 |
Why?
|
| Waldenstrom Macroglobulinemia | 22 | 2023 | 1077 | 1.530 |
Why?
|
| Neoplasm Proteins | 25 | 2022 | 3603 | 1.480 |
Why?
|
| Apoptosis | 97 | 2025 | 9523 | 1.430 |
Why?
|
| Sp1 Transcription Factor | 5 | 2016 | 143 | 1.420 |
Why?
|
| Cell Proliferation | 70 | 2025 | 10474 | 1.320 |
Why?
|
| Humans | 570 | 2025 | 768166 | 1.250 |
Why?
|
| Oligopeptides | 7 | 2024 | 1194 | 1.190 |
Why?
|
| Bone Marrow | 38 | 2023 | 2935 | 1.190 |
Why?
|
| Genomic Instability | 11 | 2024 | 716 | 1.170 |
Why?
|
| Antibodies, Monoclonal | 33 | 2022 | 9263 | 1.170 |
Why?
|
| Stem Cell Transplantation | 15 | 2022 | 1596 | 1.140 |
Why?
|
| Bone Marrow Cells | 34 | 2024 | 2414 | 1.110 |
Why?
|
| Tumor Cells, Cultured | 76 | 2021 | 6124 | 1.070 |
Why?
|
| MicroRNAs | 17 | 2023 | 3803 | 1.060 |
Why?
|
| Telomerase | 13 | 2013 | 751 | 1.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 7 | 2022 | 582 | 1.030 |
Why?
|
| Melphalan | 22 | 2024 | 421 | 1.030 |
Why?
|
| Mutation | 40 | 2025 | 30238 | 1.030 |
Why?
|
| Translocation, Genetic | 14 | 2023 | 1394 | 1.000 |
Why?
|
| Diploidy | 3 | 2025 | 140 | 0.990 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 7 | 2021 | 179 | 0.970 |
Why?
|
| HSP90 Heat-Shock Proteins | 8 | 2015 | 423 | 0.960 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2021 | 3671 | 0.950 |
Why?
|
| DNA-Binding Proteins | 29 | 2020 | 9615 | 0.950 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 38 | 2023 | 5717 | 0.940 |
Why?
|
| Dendritic Cells | 15 | 2023 | 2747 | 0.940 |
Why?
|
| Cell Survival | 42 | 2018 | 5777 | 0.900 |
Why?
|
| Tumor Microenvironment | 17 | 2024 | 3948 | 0.870 |
Why?
|
| Xenograft Model Antitumor Assays | 41 | 2025 | 3611 | 0.860 |
Why?
|
| Immunotherapy | 16 | 2024 | 4755 | 0.860 |
Why?
|
| Gene Expression Profiling | 44 | 2021 | 9538 | 0.840 |
Why?
|
| Histone Deacetylase Inhibitors | 12 | 2018 | 778 | 0.840 |
Why?
|
| Diphosphonates | 10 | 2015 | 634 | 0.820 |
Why?
|
| Osteoclasts | 14 | 2018 | 713 | 0.810 |
Why?
|
| Transplantation, Autologous | 26 | 2023 | 2120 | 0.800 |
Why?
|
| Prognosis | 60 | 2025 | 30010 | 0.790 |
Why?
|
| Receptors, Interleukin-4 | 2 | 2021 | 66 | 0.790 |
Why?
|
| 14-3-3 Proteins | 2 | 2020 | 221 | 0.780 |
Why?
|
| Stromal Cells | 34 | 2024 | 1336 | 0.780 |
Why?
|
| Enzyme Inhibitors | 26 | 2013 | 3728 | 0.780 |
Why?
|
| Imidazoles | 12 | 2015 | 1169 | 0.780 |
Why?
|
| Transcription Factors | 25 | 2025 | 12168 | 0.770 |
Why?
|
| Oncogenes | 6 | 2021 | 1234 | 0.760 |
Why?
|
| Veterans | 6 | 2024 | 2669 | 0.730 |
Why?
|
| Enhancer Elements, Genetic | 5 | 2018 | 1367 | 0.730 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 3 | 2019 | 197 | 0.720 |
Why?
|
| Immunologic Factors | 16 | 2023 | 1596 | 0.710 |
Why?
|
| Plasmacytoma | 5 | 2021 | 170 | 0.710 |
Why?
|
| Protease Inhibitors | 17 | 2012 | 751 | 0.710 |
Why?
|
| Dependovirus | 8 | 2002 | 720 | 0.690 |
Why?
|
| Proteasome Endopeptidase Complex | 19 | 2023 | 1319 | 0.690 |
Why?
|
| Transcriptional Activation | 5 | 2014 | 1750 | 0.680 |
Why?
|
| Bone Density Conservation Agents | 9 | 2021 | 797 | 0.670 |
Why?
|
| p21-Activated Kinases | 2 | 2018 | 127 | 0.670 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2024 | 633 | 0.670 |
Why?
|
| Interleukin-4 | 3 | 2021 | 1156 | 0.660 |
Why?
|
| Mice | 114 | 2025 | 82029 | 0.660 |
Why?
|
| Hydroxamic Acids | 9 | 2016 | 483 | 0.640 |
Why?
|
| Disease-Free Survival | 26 | 2024 | 6847 | 0.640 |
Why?
|
| Interleukin-17 | 3 | 2015 | 924 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2023 | 9419 | 0.630 |
Why?
|
| NF-kappa B | 30 | 2021 | 2493 | 0.620 |
Why?
|
| DNA Damage | 10 | 2021 | 2469 | 0.610 |
Why?
|
| Osteolysis | 5 | 2015 | 274 | 0.610 |
Why?
|
| Interleukin-6 | 37 | 2015 | 3228 | 0.600 |
Why?
|
| Immunoconjugates | 7 | 2021 | 975 | 0.590 |
Why?
|
| Genomics | 16 | 2023 | 5926 | 0.590 |
Why?
|
| Cell Cycle | 24 | 2024 | 2932 | 0.590 |
Why?
|
| Telomere | 10 | 2013 | 944 | 0.580 |
Why?
|
| Alternative Splicing | 2 | 2022 | 1105 | 0.580 |
Why?
|
| Animals | 135 | 2025 | 169246 | 0.580 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 10 | 2017 | 1656 | 0.580 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2018 | 716 | 0.580 |
Why?
|
| Drug Synergism | 30 | 2025 | 1760 | 0.570 |
Why?
|
| DNA Copy Number Variations | 7 | 2021 | 2048 | 0.570 |
Why?
|
| Ubiquitin | 6 | 2023 | 843 | 0.570 |
Why?
|
| Monocytes | 3 | 2023 | 2605 | 0.570 |
Why?
|
| Cancer Vaccines | 9 | 2019 | 1041 | 0.560 |
Why?
|
| Killer Cells, Natural | 10 | 2024 | 2211 | 0.560 |
Why?
|
| Antibodies, Bispecific | 3 | 2024 | 204 | 0.550 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2017 | 109 | 0.540 |
Why?
|
| Alleles | 6 | 2021 | 6894 | 0.540 |
Why?
|
| Antigens, Neoplasm | 8 | 2018 | 1997 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2025 | 998 | 0.530 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2017 | 648 | 0.530 |
Why?
|
| T-Lymphocytes | 18 | 2024 | 10266 | 0.530 |
Why?
|
| Neoplasm Transplantation | 18 | 2016 | 2014 | 0.530 |
Why?
|
| Cyclin-Dependent Kinases | 7 | 2025 | 663 | 0.530 |
Why?
|
| DNA Repair | 10 | 2018 | 2050 | 0.530 |
Why?
|
| Sulfonamides | 3 | 2024 | 1982 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 10 | 2024 | 1406 | 0.530 |
Why?
|
| Th2 Cells | 1 | 2021 | 1078 | 0.520 |
Why?
|
| Bone Diseases | 7 | 2022 | 416 | 0.520 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2015 | 15 | 0.520 |
Why?
|
| Aged | 108 | 2025 | 171504 | 0.520 |
Why?
|
| Jejunal Neoplasms | 1 | 2015 | 20 | 0.520 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2018 | 827 | 0.520 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2015 | 25 | 0.510 |
Why?
|
| Peptides | 9 | 2018 | 4354 | 0.510 |
Why?
|
| Viral Proteins | 7 | 2002 | 1802 | 0.500 |
Why?
|
| Genetic Heterogeneity | 5 | 2022 | 736 | 0.500 |
Why?
|
| Vietnam Conflict | 1 | 2015 | 101 | 0.500 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2024 | 1672 | 0.490 |
Why?
|
| Male | 147 | 2025 | 364719 | 0.490 |
Why?
|
| High Mobility Group Proteins | 6 | 2001 | 179 | 0.490 |
Why?
|
| Chromosomes, Human, Pair 14 | 6 | 2018 | 286 | 0.490 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 4 | 2018 | 85 | 0.490 |
Why?
|
| Herbicides | 1 | 2015 | 104 | 0.480 |
Why?
|
| Maytansine | 6 | 2021 | 88 | 0.480 |
Why?
|
| Salvage Therapy | 12 | 2021 | 1273 | 0.480 |
Why?
|
| Promoter Regions, Genetic | 9 | 2021 | 5797 | 0.480 |
Why?
|
| Arsenicals | 4 | 2002 | 117 | 0.470 |
Why?
|
| Chromosome Aberrations | 12 | 2022 | 1778 | 0.470 |
Why?
|
| Interferon-beta | 4 | 2001 | 349 | 0.470 |
Why?
|
| Cell Adhesion | 25 | 2016 | 3096 | 0.460 |
Why?
|
| Heavy Chain Disease | 2 | 2018 | 19 | 0.460 |
Why?
|
| Signal Transduction | 47 | 2021 | 23645 | 0.450 |
Why?
|
| Veterans Health | 1 | 2015 | 216 | 0.440 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2024 | 937 | 0.440 |
Why?
|
| Cell Transformation, Neoplastic | 11 | 2023 | 2846 | 0.430 |
Why?
|
| Oxides | 4 | 2002 | 403 | 0.430 |
Why?
|
| Down-Regulation | 20 | 2017 | 2937 | 0.430 |
Why?
|
| Middle Aged | 114 | 2025 | 223492 | 0.430 |
Why?
|
| Apoptosis Regulatory Proteins | 10 | 2024 | 1151 | 0.420 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2025 | 5703 | 0.420 |
Why?
|
| Lymph Nodes | 3 | 2018 | 3474 | 0.410 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2020 | 2433 | 0.410 |
Why?
|
| Spiro Compounds | 3 | 2007 | 69 | 0.400 |
Why?
|
| Cell Division | 27 | 2013 | 4473 | 0.400 |
Why?
|
| Receptors, Immunologic | 5 | 2014 | 1418 | 0.400 |
Why?
|
| Female | 133 | 2025 | 397192 | 0.400 |
Why?
|
| Clinical Trials as Topic | 16 | 2024 | 8054 | 0.400 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 5 | 2024 | 693 | 0.400 |
Why?
|
| Esophageal Neoplasms | 6 | 2021 | 1668 | 0.400 |
Why?
|
| Oligonucleotides | 5 | 2021 | 563 | 0.390 |
Why?
|
| Immunotoxins | 3 | 2014 | 175 | 0.390 |
Why?
|
| Gene Regulatory Networks | 3 | 2021 | 1752 | 0.390 |
Why?
|
| HLA-A2 Antigen | 4 | 2013 | 207 | 0.390 |
Why?
|
| Anabolic Agents | 1 | 2014 | 256 | 0.380 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 433 | 0.380 |
Why?
|
| Cytokines | 21 | 2018 | 7453 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2020 | 4648 | 0.380 |
Why?
|
| Necrobiotic Xanthogranuloma | 1 | 2011 | 9 | 0.380 |
Why?
|
| Barrett Esophagus | 4 | 2013 | 495 | 0.380 |
Why?
|
| Piperidines | 7 | 2021 | 1667 | 0.380 |
Why?
|
| Myeloid Cells | 3 | 2013 | 839 | 0.370 |
Why?
|
| Caspases | 20 | 2018 | 882 | 0.370 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 1230 | 0.370 |
Why?
|
| Simian virus 40 | 3 | 2002 | 292 | 0.370 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2020 | 2954 | 0.370 |
Why?
|
| Survival Rate | 24 | 2021 | 12840 | 0.370 |
Why?
|
| Recombination, Genetic | 4 | 2011 | 1525 | 0.360 |
Why?
|
| Leukocytes, Mononuclear | 8 | 2023 | 1854 | 0.360 |
Why?
|
| Phosphorylcholine | 8 | 2011 | 153 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 4 | 4 | 2017 | 378 | 0.360 |
Why?
|
| Cytotoxicity, Immunologic | 8 | 2019 | 1353 | 0.360 |
Why?
|
| Cytogenetics | 4 | 2020 | 198 | 0.360 |
Why?
|
| Rad51 Recombinase | 6 | 2018 | 191 | 0.350 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 1388 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 10 | 2009 | 225 | 0.350 |
Why?
|
| RNA, Small Interfering | 15 | 2017 | 3428 | 0.350 |
Why?
|
| Sarcoma, Kaposi | 5 | 2018 | 376 | 0.350 |
Why?
|
| Recurrence | 23 | 2021 | 8509 | 0.340 |
Why?
|
| Adenocarcinoma | 10 | 2023 | 6395 | 0.340 |
Why?
|
| Leukemia, Plasma Cell | 2 | 2022 | 46 | 0.340 |
Why?
|
| Treatment Outcome | 54 | 2024 | 65371 | 0.340 |
Why?
|
| B-Lymphocytes | 13 | 2022 | 4793 | 0.340 |
Why?
|
| SUMO-1 Protein | 1 | 2009 | 35 | 0.340 |
Why?
|
| Herpesvirus 8, Human | 3 | 2020 | 256 | 0.340 |
Why?
|
| Cell Cycle Proteins | 9 | 2025 | 3445 | 0.330 |
Why?
|
| RNA Splicing | 5 | 2019 | 905 | 0.330 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 2 | 2020 | 72 | 0.330 |
Why?
|
| Remission Induction | 14 | 2017 | 2410 | 0.330 |
Why?
|
| Cell Movement | 16 | 2024 | 5210 | 0.330 |
Why?
|
| Flow Cytometry | 19 | 2021 | 5902 | 0.330 |
Why?
|
| MAP Kinase Signaling System | 7 | 2015 | 1494 | 0.320 |
Why?
|
| Cell Communication | 9 | 2023 | 1660 | 0.320 |
Why?
|
| Epitopes | 2 | 2021 | 2528 | 0.320 |
Why?
|
| Quantitative Trait Loci | 2 | 2022 | 2131 | 0.320 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 9 | 2017 | 440 | 0.310 |
Why?
|
| Cell Line | 20 | 2014 | 15597 | 0.310 |
Why?
|
| Transfection | 19 | 2021 | 5755 | 0.310 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 3 | 2018 | 40 | 0.300 |
Why?
|
| Combined Modality Therapy | 24 | 2020 | 8542 | 0.300 |
Why?
|
| RNA Interference | 9 | 2021 | 2832 | 0.300 |
Why?
|
| Trans-Activators | 8 | 2017 | 2857 | 0.300 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2015 | 3800 | 0.300 |
Why?
|
| DNA Mutational Analysis | 8 | 2020 | 4120 | 0.300 |
Why?
|
| Immunosuppressive Agents | 9 | 2018 | 4206 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 7 | 2017 | 2830 | 0.290 |
Why?
|
| Immunotherapy, Active | 1 | 2007 | 58 | 0.290 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 771 | 0.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2018 | 614 | 0.290 |
Why?
|
| E2F1 Transcription Factor | 4 | 2025 | 182 | 0.280 |
Why?
|
| Bone Marrow Transplantation | 11 | 2018 | 2709 | 0.280 |
Why?
|
| RNA, Messenger | 19 | 2021 | 12800 | 0.280 |
Why?
|
| Renal Insufficiency | 4 | 2023 | 812 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 30 | 2019 | 10760 | 0.280 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1885 | 0.280 |
Why?
|
| Peptide Fragments | 4 | 2013 | 5151 | 0.280 |
Why?
|
| Disease Progression | 21 | 2022 | 13671 | 0.280 |
Why?
|
| Chromosome Deletion | 7 | 2021 | 1385 | 0.280 |
Why?
|
| Acrylamides | 4 | 2018 | 261 | 0.280 |
Why?
|
| Adult | 80 | 2024 | 223646 | 0.280 |
Why?
|
| Antigens, CD | 6 | 2021 | 4035 | 0.270 |
Why?
|
| Autoantigens | 2 | 2009 | 890 | 0.270 |
Why?
|
| Thymidine Kinase | 2 | 1997 | 286 | 0.270 |
Why?
|
| Cytidine Deaminase | 3 | 2025 | 249 | 0.270 |
Why?
|
| Population Groups | 1 | 2007 | 209 | 0.270 |
Why?
|
| Aged, 80 and over | 38 | 2025 | 59629 | 0.270 |
Why?
|
| Lymphocyte Activation | 11 | 2021 | 5505 | 0.270 |
Why?
|
| Receptors, CXCR4 | 3 | 2019 | 729 | 0.270 |
Why?
|
| Gene Knockdown Techniques | 5 | 2021 | 1606 | 0.270 |
Why?
|
| Immunoglobulin gamma-Chains | 2 | 2008 | 33 | 0.270 |
Why?
|
| Neoplasms | 13 | 2024 | 22371 | 0.260 |
Why?
|
| Myeloma Proteins | 4 | 2011 | 71 | 0.260 |
Why?
|
| Catechin | 1 | 2006 | 71 | 0.260 |
Why?
|
| Gene Expression | 13 | 2020 | 7598 | 0.260 |
Why?
|
| DNA Replication | 7 | 2019 | 1427 | 0.260 |
Why?
|
| Epigenesis, Genetic | 8 | 2024 | 3833 | 0.260 |
Why?
|
| Osteonecrosis | 4 | 2014 | 230 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 14 | 2020 | 4528 | 0.260 |
Why?
|
| Histone Deacetylases | 7 | 2018 | 717 | 0.260 |
Why?
|
| Transcription, Genetic | 11 | 2024 | 7608 | 0.260 |
Why?
|
| DNA, Neoplasm | 6 | 2020 | 1744 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 17 | 2013 | 2457 | 0.250 |
Why?
|
| Transplantation, Heterologous | 15 | 2010 | 2393 | 0.250 |
Why?
|
| GTP Phosphohydrolases | 3 | 2020 | 525 | 0.250 |
Why?
|
| Transduction, Genetic | 4 | 2021 | 899 | 0.250 |
Why?
|
| Phosphorylation | 25 | 2013 | 8317 | 0.250 |
Why?
|
| Zebrafish | 2 | 2016 | 3035 | 0.250 |
Why?
|
| Pyrazoles | 7 | 2016 | 2028 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-hck | 2 | 2022 | 46 | 0.240 |
Why?
|
| Disease Models, Animal | 13 | 2025 | 18349 | 0.240 |
Why?
|
| Occupational Exposure | 1 | 2015 | 1807 | 0.240 |
Why?
|
| Proteoglycans | 4 | 2005 | 809 | 0.240 |
Why?
|
| Immunoglobulin M | 4 | 2021 | 1528 | 0.240 |
Why?
|
| STAT3 Transcription Factor | 8 | 2017 | 874 | 0.240 |
Why?
|
| Genetic Vectors | 6 | 2021 | 3402 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2021 | 2892 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 10 | 2021 | 7454 | 0.240 |
Why?
|
| Insulin-Like Growth Factor I | 16 | 2010 | 1942 | 0.240 |
Why?
|
| Neoplasm Staging | 14 | 2024 | 11244 | 0.230 |
Why?
|
| Immunoglobulin kappa-Chains | 4 | 2017 | 171 | 0.230 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 977 | 0.230 |
Why?
|
| Drug Screening Assays, Antitumor | 10 | 2015 | 719 | 0.230 |
Why?
|
| Loss of Heterozygosity | 4 | 2018 | 663 | 0.230 |
Why?
|
| Anthraquinones | 1 | 2004 | 41 | 0.230 |
Why?
|
| Osteoblasts | 5 | 2016 | 1145 | 0.230 |
Why?
|
| Membrane Glycoproteins | 7 | 2021 | 3711 | 0.230 |
Why?
|
| Protein Binding | 11 | 2018 | 9343 | 0.230 |
Why?
|
| Benzoquinones | 5 | 2013 | 198 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2007 | 1245 | 0.230 |
Why?
|
| DNA Helicases | 3 | 2017 | 854 | 0.230 |
Why?
|
| Agammaglobulinemia | 2 | 2023 | 174 | 0.230 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 271 | 0.220 |
Why?
|
| Retinoblastoma Protein | 4 | 2012 | 671 | 0.220 |
Why?
|
| Bone Remodeling | 4 | 2014 | 583 | 0.220 |
Why?
|
| Mutagenesis | 3 | 2018 | 1228 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2014 | 3814 | 0.220 |
Why?
|
| Evolution, Molecular | 5 | 2023 | 1896 | 0.220 |
Why?
|
| beta Catenin | 5 | 2015 | 1047 | 0.220 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2023 | 2521 | 0.220 |
Why?
|
| Genes, bcl-2 | 2 | 2003 | 119 | 0.220 |
Why?
|
| Proteins | 7 | 2023 | 6009 | 0.220 |
Why?
|
| DNA | 9 | 2017 | 7214 | 0.210 |
Why?
|
| src-Family Kinases | 3 | 2022 | 539 | 0.210 |
Why?
|
| Cyclophosphamide | 9 | 2023 | 2227 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2018 | 1399 | 0.210 |
Why?
|
| Blotting, Western | 14 | 2017 | 5027 | 0.210 |
Why?
|
| Lactams, Macrocyclic | 5 | 2013 | 319 | 0.210 |
Why?
|
| Azepines | 2 | 2018 | 329 | 0.210 |
Why?
|
| Coculture Techniques | 13 | 2016 | 1340 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2022 | 18065 | 0.210 |
Why?
|
| Maximum Tolerated Dose | 5 | 2021 | 899 | 0.210 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 57 | 0.210 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2024 | 1074 | 0.210 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 801 | 0.210 |
Why?
|
| Gene Expression Regulation | 10 | 2013 | 11928 | 0.210 |
Why?
|
| Medical Oncology | 3 | 2013 | 2346 | 0.210 |
Why?
|
| Aminopyridines | 2 | 2018 | 580 | 0.200 |
Why?
|
| Gene Dosage | 5 | 2018 | 1219 | 0.200 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2009 | 1966 | 0.200 |
Why?
|
| Oxazoles | 1 | 2004 | 199 | 0.200 |
Why?
|
| Transplantation Conditioning | 4 | 2007 | 1601 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 11 | 2016 | 428 | 0.200 |
Why?
|
| Recombinant Proteins | 12 | 2013 | 6514 | 0.200 |
Why?
|
| Genes, p53 | 2 | 2015 | 714 | 0.200 |
Why?
|
| Lymphopenia | 1 | 2025 | 300 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2021 | 1375 | 0.200 |
Why?
|
| bcl-X Protein | 2 | 2018 | 412 | 0.200 |
Why?
|
| Caspase 3 | 7 | 2016 | 730 | 0.200 |
Why?
|
| Enzyme Activation | 14 | 2012 | 3590 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2021 | 1505 | 0.200 |
Why?
|
| Th1 Cells | 2 | 2021 | 1042 | 0.200 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2017 | 101 | 0.190 |
Why?
|
| Bone Resorption | 5 | 2014 | 728 | 0.190 |
Why?
|
| RNA, Neoplasm | 4 | 2018 | 749 | 0.190 |
Why?
|
| Lysine | 3 | 2021 | 1000 | 0.190 |
Why?
|
| Education | 3 | 2019 | 533 | 0.190 |
Why?
|
| Luminescent Measurements | 3 | 2014 | 342 | 0.190 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 263 | 0.190 |
Why?
|
| Vaccines, Subunit | 2 | 2012 | 159 | 0.190 |
Why?
|
| DNA, Intergenic | 1 | 2022 | 108 | 0.190 |
Why?
|
| Survival Analysis | 16 | 2022 | 10101 | 0.190 |
Why?
|
| Porphyrins | 1 | 2003 | 352 | 0.190 |
Why?
|
| Cell Differentiation | 13 | 2021 | 11669 | 0.190 |
Why?
|
| Cell Transformation, Viral | 2 | 2003 | 530 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 13 | 7 | 2021 | 192 | 0.190 |
Why?
|
| Heterocyclic Compounds | 3 | 2019 | 245 | 0.190 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 2 | 2018 | 55 | 0.190 |
Why?
|
| Hematologic Diseases | 3 | 2021 | 498 | 0.180 |
Why?
|
| Genome-Wide Association Study | 5 | 2018 | 12795 | 0.180 |
Why?
|
| Disease Management | 5 | 2024 | 2536 | 0.180 |
Why?
|
| Cells, Cultured | 19 | 2018 | 19015 | 0.180 |
Why?
|
| Mice, Inbred NOD | 7 | 2021 | 1837 | 0.180 |
Why?
|
| Consensus | 5 | 2023 | 3212 | 0.180 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2002 | 256 | 0.180 |
Why?
|
| Benzimidazoles | 4 | 2015 | 864 | 0.180 |
Why?
|
| Immunoglobulin Idiotypes | 4 | 2007 | 201 | 0.180 |
Why?
|
| Pinocytosis | 1 | 2001 | 63 | 0.180 |
Why?
|
| Single-Cell Analysis | 3 | 2023 | 2540 | 0.180 |
Why?
|
| Endonucleases | 2 | 2020 | 371 | 0.180 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2001 | 1839 | 0.180 |
Why?
|
| Immunoblotting | 11 | 2015 | 1647 | 0.180 |
Why?
|
| I-kappa B Kinase | 5 | 2009 | 250 | 0.180 |
Why?
|
| Fatigue | 4 | 2022 | 1557 | 0.180 |
Why?
|
| Genes, Viral | 1 | 2002 | 655 | 0.180 |
Why?
|
| Antigen Presentation | 3 | 2007 | 1251 | 0.180 |
Why?
|
| Sirolimus | 5 | 2014 | 1540 | 0.180 |
Why?
|
| Nuclear Proteins | 8 | 2025 | 5804 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2015 | 418 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 2040 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 7 | 2013 | 6082 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2024 | 2909 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2018 | 16045 | 0.170 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 1907 | 0.170 |
Why?
|
| Adenovirus E1B Proteins | 1 | 1999 | 15 | 0.170 |
Why?
|
| Urea | 2 | 2013 | 448 | 0.170 |
Why?
|
| Immune Tolerance | 3 | 2018 | 2323 | 0.170 |
Why?
|
| Focal Adhesion Kinase 2 | 3 | 2014 | 87 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 4 | 2021 | 6231 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2018 | 3114 | 0.170 |
Why?
|
| Whole-Body Irradiation | 2 | 2000 | 435 | 0.170 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2000 | 147 | 0.170 |
Why?
|
| Ganciclovir | 2 | 1997 | 256 | 0.170 |
Why?
|
| Lymphokines | 4 | 2002 | 924 | 0.170 |
Why?
|
| Adenine | 3 | 2021 | 995 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2022 | 945 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2018 | 411 | 0.160 |
Why?
|
| HeLa Cells | 7 | 2003 | 3074 | 0.160 |
Why?
|
| Base Sequence | 7 | 2023 | 12421 | 0.160 |
Why?
|
| Genome, Human | 3 | 2019 | 4446 | 0.160 |
Why?
|
| Endothelial Growth Factors | 3 | 2002 | 671 | 0.160 |
Why?
|
| INDEL Mutation | 1 | 2020 | 267 | 0.160 |
Why?
|
| Karyotyping | 6 | 2013 | 1177 | 0.160 |
Why?
|
| Pyrimidines | 7 | 2024 | 3048 | 0.160 |
Why?
|
| K562 Cells | 5 | 2013 | 644 | 0.160 |
Why?
|
| Transcription Factor DP1 | 1 | 2018 | 136 | 0.160 |
Why?
|
| Indoles | 5 | 2011 | 1836 | 0.160 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 404 | 0.160 |
Why?
|
| Up-Regulation | 12 | 2020 | 4146 | 0.160 |
Why?
|
| Repressor Proteins | 4 | 2022 | 2982 | 0.160 |
Why?
|
| NAD | 2 | 2013 | 618 | 0.160 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 386 | 0.150 |
Why?
|
| Mice, Nude | 4 | 2017 | 3623 | 0.150 |
Why?
|
| Exons | 2 | 2022 | 2394 | 0.150 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2018 | 62 | 0.150 |
Why?
|
| Cell Polarity | 1 | 2021 | 639 | 0.150 |
Why?
|
| Galectins | 1 | 2021 | 295 | 0.150 |
Why?
|
| Cell Death | 6 | 2016 | 1679 | 0.150 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 12 | 0.150 |
Why?
|
| Heat-Shock Proteins | 8 | 2008 | 797 | 0.150 |
Why?
|
| Quality of Life | 6 | 2024 | 13490 | 0.150 |
Why?
|
| Cohort Studies | 8 | 2022 | 41754 | 0.150 |
Why?
|
| RNA Precursors | 1 | 2019 | 196 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 5 | 2012 | 474 | 0.150 |
Why?
|
| Immunophenotyping | 4 | 2019 | 1864 | 0.150 |
Why?
|
| Phenotype | 7 | 2020 | 16726 | 0.150 |
Why?
|
| Cytoskeletal Proteins | 3 | 2002 | 1327 | 0.150 |
Why?
|
| Receptors, Interleukin-6 | 5 | 2005 | 224 | 0.150 |
Why?
|
| Jaw Diseases | 2 | 2009 | 91 | 0.150 |
Why?
|
| Follow-Up Studies | 18 | 2023 | 39348 | 0.150 |
Why?
|
| Lymphoma | 3 | 2021 | 1898 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 5 | 2012 | 478 | 0.150 |
Why?
|
| Cisplatin | 4 | 2020 | 1660 | 0.150 |
Why?
|
| Nuclear Factor 45 Protein | 1 | 2017 | 5 | 0.150 |
Why?
|
| DNA, Complementary | 5 | 2013 | 1989 | 0.150 |
Why?
|
| Secondary Prevention | 2 | 2014 | 1474 | 0.150 |
Why?
|
| Acetylation | 6 | 2016 | 1056 | 0.150 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 89 | 0.140 |
Why?
|
| Stavudine | 1 | 1997 | 85 | 0.140 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2017 | 31 | 0.140 |
Why?
|
| Thioguanine | 1 | 1997 | 45 | 0.140 |
Why?
|
| Immunoglobulin G | 7 | 2021 | 4568 | 0.140 |
Why?
|
| DNA, Recombinant | 1 | 1997 | 455 | 0.140 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 241 | 0.140 |
Why?
|
| Amino Acid Substitution | 2 | 2019 | 1743 | 0.140 |
Why?
|
| Polyadenylation | 1 | 2018 | 114 | 0.140 |
Why?
|
| Virus Assembly | 1 | 1997 | 140 | 0.140 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2022 | 724 | 0.140 |
Why?
|
| Membrane Proteins | 6 | 2021 | 7876 | 0.140 |
Why?
|
| Binding Sites | 5 | 2016 | 6020 | 0.140 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2021 | 615 | 0.140 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2017 | 129 | 0.140 |
Why?
|
| Congresses as Topic | 2 | 2019 | 812 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2015 | 4580 | 0.140 |
Why?
|
| Parvovirus B19, Human | 2 | 1996 | 42 | 0.140 |
Why?
|
| Immunologic Memory | 4 | 2018 | 1377 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2021 | 2056 | 0.140 |
Why?
|
| Gene Transfer Techniques | 2 | 1999 | 1207 | 0.140 |
Why?
|
| DNA, Viral | 3 | 2002 | 2204 | 0.130 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2016 | 91 | 0.130 |
Why?
|
| Models, Biological | 10 | 2018 | 9495 | 0.130 |
Why?
|
| Receptors, Chemokine | 1 | 1999 | 652 | 0.130 |
Why?
|
| Risk Factors | 12 | 2022 | 74944 | 0.130 |
Why?
|
| Allosteric Regulation | 2 | 2017 | 426 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2018 | 462 | 0.130 |
Why?
|
| Mitochondrial Proteins | 4 | 2006 | 979 | 0.130 |
Why?
|
| Purines | 3 | 2010 | 615 | 0.130 |
Why?
|
| Tumor Burden | 8 | 2015 | 1906 | 0.130 |
Why?
|
| Protein Subunits | 2 | 2018 | 943 | 0.130 |
Why?
|
| Chromatin | 3 | 2023 | 2981 | 0.130 |
Why?
|
| Etodolac | 2 | 2006 | 19 | 0.130 |
Why?
|
| Drug Administration Schedule | 10 | 2018 | 4860 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 6 | 2001 | 631 | 0.130 |
Why?
|
| Cytarabine | 2 | 1999 | 695 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2021 | 1191 | 0.130 |
Why?
|
| Stress, Physiological | 3 | 2012 | 1408 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2016 | 229 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 1014 | 0.130 |
Why?
|
| Immunomodulation | 2 | 2020 | 549 | 0.130 |
Why?
|
| Multienzyme Complexes | 6 | 2003 | 664 | 0.120 |
Why?
|
| Antigens, CD34 | 6 | 2005 | 657 | 0.120 |
Why?
|
| Zidovudine | 1 | 1997 | 625 | 0.120 |
Why?
|
| Introns | 1 | 2018 | 966 | 0.120 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2015 | 71 | 0.120 |
Why?
|
| Clodronic Acid | 2 | 2013 | 60 | 0.120 |
Why?
|
| Penetrance | 1 | 2017 | 385 | 0.120 |
Why?
|
| Cell Growth Processes | 3 | 2011 | 381 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 1437 | 0.120 |
Why?
|
| Cyclophilin A | 1 | 2015 | 57 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2012 | 289 | 0.120 |
Why?
|
| Graft vs Tumor Effect | 2 | 2005 | 68 | 0.120 |
Why?
|
| Natural Language Processing | 1 | 2024 | 1203 | 0.120 |
Why?
|
| Internationality | 1 | 2020 | 1008 | 0.120 |
Why?
|
| Adenoviridae | 1 | 1999 | 1092 | 0.120 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 3 | 1996 | 49 | 0.120 |
Why?
|
| Genotype | 3 | 2018 | 13045 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 1560 | 0.120 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 168 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2017 | 356 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2015 | 151 | 0.120 |
Why?
|
| Growth Inhibitors | 3 | 2002 | 375 | 0.120 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 4 | 2012 | 306 | 0.120 |
Why?
|
| Casein Kinase Ialpha | 1 | 2014 | 26 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 4 | 2008 | 1133 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 9 | 2013 | 2631 | 0.120 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1994 | 42 | 0.120 |
Why?
|
| Biphenyl Compounds | 2 | 2012 | 1026 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2021 | 4428 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2010 | 2885 | 0.120 |
Why?
|
| Sulfonylurea Compounds | 2 | 1993 | 220 | 0.120 |
Why?
|
| Cell Degranulation | 2 | 2012 | 277 | 0.120 |
Why?
|
| Doxorubicin | 9 | 2018 | 2234 | 0.120 |
Why?
|
| Lymphotoxin-beta | 1 | 2014 | 14 | 0.120 |
Why?
|
| Lymphocytes | 4 | 2004 | 2614 | 0.110 |
Why?
|
| Genome, Mitochondrial | 1 | 2014 | 68 | 0.110 |
Why?
|
| Drug Therapy, Combination | 7 | 2014 | 6316 | 0.110 |
Why?
|
| Pseudogenes | 1 | 2014 | 104 | 0.110 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2015 | 281 | 0.110 |
Why?
|
| Chemokine CCL20 | 1 | 2014 | 64 | 0.110 |
Why?
|
| RNA, Antisense | 2 | 2013 | 136 | 0.110 |
Why?
|
| Antibodies | 3 | 2007 | 2421 | 0.110 |
Why?
|
| Receptors, CCR6 | 1 | 2014 | 73 | 0.110 |
Why?
|
| Hematopoiesis | 3 | 2020 | 2059 | 0.110 |
Why?
|
| Cryoglobulinemia | 2 | 2012 | 84 | 0.110 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2014 | 133 | 0.110 |
Why?
|
| DNA, Mitochondrial | 2 | 2020 | 872 | 0.110 |
Why?
|
| Neural Cell Adhesion Molecules | 2 | 2004 | 122 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2008 | 341 | 0.110 |
Why?
|
| Genes, APC | 1 | 2014 | 145 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2023 | 892 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 4786 | 0.110 |
Why?
|
| Databases, Genetic | 2 | 2018 | 1758 | 0.110 |
Why?
|
| Antigens, Surface | 2 | 2009 | 1617 | 0.110 |
Why?
|
| Infusions, Intravenous | 6 | 2019 | 2230 | 0.110 |
Why?
|
| Protein Multimerization | 1 | 2018 | 965 | 0.110 |
Why?
|
| Societies, Medical | 3 | 2020 | 3968 | 0.110 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 50 | 0.110 |
Why?
|
| Ikaros Transcription Factor | 2 | 2013 | 233 | 0.110 |
Why?
|
| Computational Biology | 4 | 2021 | 3568 | 0.110 |
Why?
|
| Receptors, Growth Factor | 3 | 2006 | 324 | 0.110 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 130 | 0.110 |
Why?
|
| Histones | 6 | 2024 | 2601 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2017 | 2810 | 0.110 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 183 | 0.110 |
Why?
|
| Triazoles | 1 | 2018 | 904 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2016 | 1524 | 0.110 |
Why?
|
| B-Cell Activating Factor | 3 | 2008 | 116 | 0.110 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2013 | 56 | 0.110 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1994 | 189 | 0.110 |
Why?
|
| HMGA1a Protein | 4 | 2001 | 63 | 0.110 |
Why?
|
| Receptors, Cell Surface | 3 | 2012 | 2819 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2015 | 1062 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 3626 | 0.110 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2013 | 93 | 0.100 |
Why?
|
| Osteogenesis | 3 | 2009 | 1288 | 0.100 |
Why?
|
| Genes, ras | 1 | 2015 | 663 | 0.100 |
Why?
|
| Protein Kinase C | 2 | 2008 | 1207 | 0.100 |
Why?
|
| Interferon-gamma | 3 | 2015 | 3160 | 0.100 |
Why?
|
| Pain | 4 | 2022 | 5100 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 507 | 0.100 |
Why?
|
| Acetylcysteine | 2 | 2003 | 262 | 0.100 |
Why?
|
| Sirtuins | 1 | 2015 | 322 | 0.100 |
Why?
|
| Pyridines | 4 | 2012 | 2894 | 0.100 |
Why?
|
| Interleukin-3 | 2 | 2014 | 425 | 0.100 |
Why?
|
| Mesna | 1 | 1992 | 62 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2012 | 362 | 0.100 |
Why?
|
| Dysgerminoma | 1 | 1992 | 66 | 0.100 |
Why?
|
| Estradiol | 4 | 2004 | 1951 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2021 | 637 | 0.100 |
Why?
|
| Cryoglobulins | 1 | 2012 | 58 | 0.100 |
Why?
|
| Fractures, Spontaneous | 1 | 2014 | 232 | 0.100 |
Why?
|
| Acyltransferases | 2 | 2005 | 306 | 0.100 |
Why?
|
| Polyploidy | 1 | 2013 | 120 | 0.100 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 3781 | 0.100 |
Why?
|
| Amino Acid Sequence | 5 | 2017 | 13421 | 0.100 |
Why?
|
| Karyopherins | 1 | 2013 | 134 | 0.100 |
Why?
|
| Molecular Sequence Data | 8 | 2013 | 17622 | 0.100 |
Why?
|
| Genetic Testing | 2 | 2017 | 3591 | 0.100 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 234 | 0.100 |
Why?
|
| Cluster Analysis | 6 | 2022 | 2732 | 0.100 |
Why?
|
| Syndecans | 4 | 2005 | 75 | 0.100 |
Why?
|
| Models, Genetic | 3 | 2019 | 3447 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 622 | 0.100 |
Why?
|
| Benzamides | 2 | 2015 | 1379 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.100 |
Why?
|
| Cysteine Endopeptidases | 6 | 2003 | 542 | 0.100 |
Why?
|
| Prevalence | 3 | 2021 | 15869 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 696 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2024 | 1887 | 0.100 |
Why?
|
| Erythroid Precursor Cells | 1 | 1993 | 211 | 0.100 |
Why?
|
| Immunization | 3 | 2013 | 1219 | 0.100 |
Why?
|
| Inflammation | 3 | 2024 | 10873 | 0.100 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2011 | 20 | 0.100 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2012 | 73 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 2055 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 1886 | 0.100 |
Why?
|
| Ifosfamide | 1 | 1992 | 233 | 0.100 |
Why?
|
| CD40 Ligand | 4 | 2006 | 528 | 0.100 |
Why?
|
| Adenovirus E1A Proteins | 2 | 2002 | 81 | 0.100 |
Why?
|
| Herpesvirus 1, Human | 1 | 1997 | 743 | 0.100 |
Why?
|
| RNA Polymerase II | 2 | 2021 | 549 | 0.100 |
Why?
|
| Intestinal Neoplasms | 1 | 2014 | 314 | 0.100 |
Why?
|
| Positron-Emission Tomography | 6 | 2016 | 6669 | 0.090 |
Why?
|
| Phenylalanine | 1 | 2013 | 367 | 0.090 |
Why?
|
| Lymphocyte Transfusion | 2 | 2003 | 232 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2017 | 1183 | 0.090 |
Why?
|
| Point Mutation | 2 | 2019 | 1596 | 0.090 |
Why?
|
| Spleen | 3 | 2008 | 2295 | 0.090 |
Why?
|
| Administration, Oral | 8 | 2018 | 4030 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 701 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 858 | 0.090 |
Why?
|
| Interferon-alpha | 3 | 2001 | 910 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2014 | 753 | 0.090 |
Why?
|
| Autophagy | 5 | 2024 | 1349 | 0.090 |
Why?
|
| Hematuria | 1 | 1992 | 232 | 0.090 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 1997 | 0.090 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2010 | 93 | 0.090 |
Why?
|
| RNA | 3 | 2014 | 2720 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 1767 | 0.090 |
Why?
|
| Mitochondria | 7 | 2020 | 3681 | 0.090 |
Why?
|
| Case-Control Studies | 10 | 2021 | 22291 | 0.090 |
Why?
|
| Retrospective Studies | 15 | 2025 | 81762 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 1993 | 211 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 11095 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2017 | 2059 | 0.090 |
Why?
|
| Alu Elements | 1 | 2011 | 115 | 0.090 |
Why?
|
| Immunity, Cellular | 3 | 2021 | 1561 | 0.090 |
Why?
|
| Transplantation, Homologous | 7 | 2009 | 4833 | 0.090 |
Why?
|
| United States | 8 | 2024 | 73039 | 0.090 |
Why?
|
| beta 2-Microglobulin | 5 | 2005 | 330 | 0.090 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 371 | 0.090 |
Why?
|
| Lymphocyte Count | 2 | 2025 | 794 | 0.090 |
Why?
|
| Endoribonucleases | 1 | 2012 | 231 | 0.090 |
Why?
|
| Interleukin-2 | 2 | 2013 | 1895 | 0.090 |
Why?
|
| Iodine Radioisotopes | 1 | 1994 | 1034 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 5 | 2014 | 2065 | 0.090 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 482 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 952 | 0.090 |
Why?
|
| Software | 3 | 2017 | 4478 | 0.090 |
Why?
|
| Cell Nucleus | 4 | 2003 | 2885 | 0.090 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2009 | 30 | 0.090 |
Why?
|
| Polymers | 2 | 2023 | 1630 | 0.090 |
Why?
|
| Bone Transplantation | 2 | 2005 | 925 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 1384 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 2011 | 0.090 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 82 | 0.080 |
Why?
|
| Bone and Bones | 3 | 2009 | 2589 | 0.080 |
Why?
|
| CREB-Binding Protein | 2 | 2001 | 147 | 0.080 |
Why?
|
| Plasmids | 2 | 2014 | 2269 | 0.080 |
Why?
|
| Lysosomes | 1 | 2015 | 938 | 0.080 |
Why?
|
| Substrate Specificity | 4 | 2019 | 1751 | 0.080 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2012 | 287 | 0.080 |
Why?
|
| Glycoproteins | 2 | 2016 | 2202 | 0.080 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 68 | 0.080 |
Why?
|
| 3' Untranslated Regions | 3 | 2018 | 515 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1901 | 0.080 |
Why?
|
| Dental Fistula | 1 | 2009 | 12 | 0.080 |
Why?
|
| Algorithms | 4 | 2024 | 14164 | 0.080 |
Why?
|
| Nanoparticles | 2 | 2019 | 1985 | 0.080 |
Why?
|
| Cyclin D1 | 2 | 2009 | 453 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2016 | 3623 | 0.080 |
Why?
|
| Time Factors | 18 | 2019 | 40218 | 0.080 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2010 | 331 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 2 | 2012 | 942 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 581 | 0.080 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 465 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 528 | 0.080 |
Why?
|
| Ligands | 6 | 2018 | 3284 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2009 | 69 | 0.080 |
Why?
|
| Carrier Proteins | 4 | 2023 | 4937 | 0.080 |
Why?
|
| Acetyltransferases | 2 | 2001 | 231 | 0.080 |
Why?
|
| Gene Targeting | 1 | 2012 | 841 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1996 | 0.080 |
Why?
|
| Flavones | 1 | 2009 | 66 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2013 | 812 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2002 | 435 | 0.080 |
Why?
|
| Tyrosine | 3 | 2003 | 1427 | 0.080 |
Why?
|
| Immunization, Passive | 3 | 2005 | 619 | 0.080 |
Why?
|
| Age Factors | 2 | 2025 | 18412 | 0.080 |
Why?
|
| Lac Operon | 2 | 1999 | 237 | 0.080 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2008 | 65 | 0.080 |
Why?
|
| Quinazolinones | 1 | 2010 | 219 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 859 | 0.080 |
Why?
|
| ras Proteins | 1 | 2014 | 1058 | 0.080 |
Why?
|
| Activins | 1 | 2010 | 211 | 0.080 |
Why?
|
| Phosphoproteins | 3 | 2011 | 2451 | 0.080 |
Why?
|
| Macromolecular Substances | 3 | 2000 | 1435 | 0.080 |
Why?
|
| Lentivirus | 4 | 2014 | 518 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1942 | 0.080 |
Why?
|
| Blood Component Removal | 1 | 2009 | 132 | 0.080 |
Why?
|
| Benzylamines | 3 | 2019 | 251 | 0.080 |
Why?
|
| Germinal Center | 2 | 2021 | 380 | 0.070 |
Why?
|
| Histone Acetyltransferases | 2 | 2001 | 335 | 0.070 |
Why?
|
| Thiophenes | 1 | 2012 | 570 | 0.070 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 559 | 0.070 |
Why?
|
| Antigens, Viral | 2 | 2021 | 995 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2006 | 748 | 0.070 |
Why?
|
| Hydroxyurea | 2 | 2001 | 284 | 0.070 |
Why?
|
| Pyrroles | 2 | 2020 | 1124 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2023 | 9384 | 0.070 |
Why?
|
| Sequence Deletion | 2 | 2013 | 1497 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 414 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 1642 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2008 | 96 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2006 | 4352 | 0.070 |
Why?
|
| Niacinamide | 1 | 2010 | 418 | 0.070 |
Why?
|
| Consensus Development Conferences as Topic | 3 | 2014 | 169 | 0.070 |
Why?
|
| RNA-Binding Proteins | 2 | 2023 | 1890 | 0.070 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 715 | 0.070 |
Why?
|
| Immunity | 3 | 2021 | 1003 | 0.070 |
Why?
|
| Natural Killer T-Cells | 1 | 2010 | 318 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2002 | 681 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1061 | 0.070 |
Why?
|
| Growth Substances | 2 | 2006 | 759 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 20227 | 0.070 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2006 | 11 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2271 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2020 | 1338 | 0.070 |
Why?
|
| Mutation, Missense | 2 | 2014 | 2592 | 0.070 |
Why?
|
| Tetanus Toxoid | 1 | 2007 | 188 | 0.070 |
Why?
|
| Aphidicolin | 2 | 2001 | 37 | 0.070 |
Why?
|
| Receptors, Laminin | 1 | 2006 | 26 | 0.070 |
Why?
|
| Phorbol Esters | 1 | 2006 | 109 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4887 | 0.070 |
Why?
|
| Authorship | 1 | 2010 | 289 | 0.070 |
Why?
|
| Cytotoxins | 1 | 2007 | 154 | 0.070 |
Why?
|
| Prospective Studies | 7 | 2023 | 54926 | 0.070 |
Why?
|
| Mice, Transgenic | 6 | 2020 | 9561 | 0.070 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2006 | 80 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 2008 | 319 | 0.070 |
Why?
|
| Incidence | 6 | 2015 | 21538 | 0.070 |
Why?
|
| Caspase 9 | 5 | 2005 | 184 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2006 | 169 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6526 | 0.060 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 434 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2011 | 1146 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2006 | 108 | 0.060 |
Why?
|
| Injections, Subcutaneous | 2 | 2018 | 687 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 130 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2008 | 444 | 0.060 |
Why?
|
| I-kappa B Proteins | 4 | 2009 | 210 | 0.060 |
Why?
|
| Superoxides | 2 | 2004 | 389 | 0.060 |
Why?
|
| Rifabutin | 1 | 2005 | 59 | 0.060 |
Why?
|
| Neutropenia | 4 | 2009 | 892 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2003 | 185 | 0.060 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 2565 | 0.060 |
Why?
|
| Hydrolases | 1 | 2006 | 146 | 0.060 |
Why?
|
| Precipitin Tests | 2 | 2003 | 816 | 0.060 |
Why?
|
| Paraproteins | 1 | 2005 | 38 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2009 | 3514 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 489 | 0.060 |
Why?
|
| Lactones | 1 | 2007 | 316 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2020 | 5107 | 0.060 |
Why?
|
| Hematology | 2 | 2019 | 243 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 556 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2008 | 855 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 1351 | 0.060 |
Why?
|
| Chromosomes, Human | 2 | 2019 | 438 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 1247 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2005 | 139 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 10590 | 0.060 |
Why?
|
| Tea | 1 | 2006 | 290 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2017 | 36743 | 0.060 |
Why?
|
| Glucocorticoids | 4 | 2009 | 2167 | 0.060 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2004 | 108 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 1997 | 3073 | 0.060 |
Why?
|
| Piperazines | 3 | 2009 | 2554 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2006 | 298 | 0.060 |
Why?
|
| Thrombocytopenia | 3 | 2020 | 1179 | 0.060 |
Why?
|
| Etoposide | 5 | 1999 | 639 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2014 | 2474 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 755 | 0.060 |
Why?
|
| Oleanolic Acid | 1 | 2003 | 43 | 0.060 |
Why?
|
| Mutagens | 2 | 2015 | 181 | 0.060 |
Why?
|
| Isoantibodies | 1 | 2008 | 681 | 0.060 |
Why?
|
| Quinolines | 1 | 2009 | 772 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2010 | 3463 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2009 | 3409 | 0.050 |
Why?
|
| Neck | 1 | 2008 | 736 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 3 | 2009 | 351 | 0.050 |
Why?
|
| Reactive Oxygen Species | 3 | 2018 | 2149 | 0.050 |
Why?
|
| Drug Industry | 1 | 2010 | 791 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 1793 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 8080 | 0.050 |
Why?
|
| Calreticulin | 1 | 2024 | 115 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2004 | 170 | 0.050 |
Why?
|
| Stem Cells | 4 | 2010 | 3537 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2002 | 1627 | 0.050 |
Why?
|
| Anti-HIV Agents | 2 | 2009 | 4573 | 0.050 |
Why?
|
| Phylogeny | 2 | 2022 | 2843 | 0.050 |
Why?
|
| Cell Count | 2 | 2017 | 1832 | 0.050 |
Why?
|
| Caveolae | 1 | 2002 | 54 | 0.050 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2004 | 154 | 0.050 |
Why?
|
| Deoxyribonuclease I | 1 | 2003 | 228 | 0.050 |
Why?
|
| Graft Survival | 3 | 2007 | 3887 | 0.050 |
Why?
|
| Tubulin | 1 | 2006 | 695 | 0.050 |
Why?
|
| Carboplatin | 3 | 2020 | 797 | 0.050 |
Why?
|
| Centrosome | 1 | 2024 | 210 | 0.050 |
Why?
|
| Discitis | 1 | 2003 | 45 | 0.050 |
Why?
|
| Drug Resistance | 3 | 2003 | 1599 | 0.050 |
Why?
|
| Mast Cells | 2 | 2008 | 1406 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2012 | 2486 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 587 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2002 | 60 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 3620 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 176 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2011 | 640 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 2541 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2023 | 186 | 0.050 |
Why?
|
| Trisomy | 2 | 2013 | 260 | 0.050 |
Why?
|
| Clone Cells | 2 | 2018 | 1670 | 0.050 |
Why?
|
| Deoxyribonucleases | 1 | 2023 | 209 | 0.050 |
Why?
|
| Respirovirus | 1 | 2001 | 31 | 0.050 |
Why?
|
| Vaccination | 3 | 2022 | 3437 | 0.050 |
Why?
|
| Health Status | 1 | 2015 | 4091 | 0.050 |
Why?
|
| RANK Ligand | 3 | 2008 | 321 | 0.050 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 863 | 0.050 |
Why?
|
| Protein Kinases | 2 | 2009 | 1611 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2003 | 472 | 0.050 |
Why?
|
| Antigens | 1 | 2007 | 1442 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2022 | 2661 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2015 | 618 | 0.050 |
Why?
|
| Environment | 1 | 2007 | 1121 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2003 | 447 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2021 | 56 | 0.050 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2021 | 35 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5520 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 1361 | 0.050 |
Why?
|
| Helper Viruses | 1 | 2001 | 39 | 0.050 |
Why?
|
| Blood Group Incompatibility | 1 | 2002 | 134 | 0.050 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2001 | 69 | 0.050 |
Why?
|
| Antigenic Variation | 1 | 2021 | 117 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2002 | 642 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2021 | 68 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2001 | 205 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 600 | 0.050 |
Why?
|
| Seizures | 1 | 2014 | 2998 | 0.050 |
Why?
|
| G-Quadruplexes | 1 | 2003 | 144 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 4413 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2021 | 113 | 0.050 |
Why?
|
| Isoquinolines | 2 | 2017 | 354 | 0.050 |
Why?
|
| Ubiquitination | 2 | 2017 | 1009 | 0.050 |
Why?
|
| Tissue Donors | 3 | 2005 | 2381 | 0.040 |
Why?
|
| Internet | 1 | 2013 | 3110 | 0.040 |
Why?
|
| Polyneuropathies | 2 | 2014 | 139 | 0.040 |
Why?
|
| E2F Transcription Factors | 1 | 2001 | 270 | 0.040 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2001 | 148 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 20760 | 0.040 |
Why?
|
| HEK293 Cells | 3 | 2014 | 4283 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 921 | 0.040 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2004 | 336 | 0.040 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2001 | 153 | 0.040 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2022 | 169 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 420 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8748 | 0.040 |
Why?
|
| Membrane Potentials | 4 | 2004 | 1090 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2009 | 2575 | 0.040 |
Why?
|
| Young Adult | 5 | 2024 | 60066 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2000 | 176 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2012 | 2062 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 22379 | 0.040 |
Why?
|
| Epirubicin | 1 | 2000 | 82 | 0.040 |
Why?
|
| Immunoglobulin A | 2 | 2001 | 992 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2003 | 1082 | 0.040 |
Why?
|
| Nephritis | 1 | 2020 | 147 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2021 | 404 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2012 | 3589 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2001 | 348 | 0.040 |
Why?
|
| Gene Library | 2 | 2018 | 1064 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2000 | 120 | 0.040 |
Why?
|
| Phthalazines | 1 | 2002 | 397 | 0.040 |
Why?
|
| Electroporation | 1 | 2021 | 239 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2008 | 2766 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2021 | 2675 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2022 | 344 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2012 | 3080 | 0.040 |
Why?
|
| Membrane Microdomains | 2 | 2015 | 205 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2003 | 460 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2001 | 4176 | 0.040 |
Why?
|
| Skin Diseases | 2 | 2007 | 1085 | 0.040 |
Why?
|
| Genetics | 1 | 2020 | 114 | 0.040 |
Why?
|
| Tumor Lysis Syndrome | 1 | 1999 | 38 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 13014 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 866 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 114 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 183 | 0.040 |
Why?
|
| TCF Transcription Factors | 2 | 2012 | 138 | 0.040 |
Why?
|
| Chloroquine | 1 | 2001 | 276 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2002 | 381 | 0.040 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 1999 | 16 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 2596 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2021 | 1065 | 0.040 |
Why?
|
| Anemia | 1 | 2009 | 1514 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2001 | 452 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 242 | 0.040 |
Why?
|
| Transcription Factors, TFII | 1 | 1999 | 62 | 0.040 |
Why?
|
| Cytochrome c Group | 3 | 2003 | 123 | 0.040 |
Why?
|
| Chromatin Assembly Factor-1 | 1 | 1998 | 21 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2021 | 527 | 0.040 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2000 | 203 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2020 | 303 | 0.040 |
Why?
|
| Organelles | 1 | 2001 | 265 | 0.040 |
Why?
|
| RNA Editing | 1 | 2020 | 150 | 0.040 |
Why?
|
| Caspase 8 | 3 | 2005 | 198 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 1815 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2003 | 147 | 0.040 |
Why?
|
| Kinetics | 3 | 2017 | 6329 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1465 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14729 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 1703 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 2 | 2007 | 1613 | 0.040 |
Why?
|
| Mitosis | 1 | 2024 | 1178 | 0.040 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2018 | 37 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2008 | 1382 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2018 | 94 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2019 | 2359 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 1999 | 311 | 0.040 |
Why?
|
| Transcription Factor TFIID | 1 | 1999 | 150 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 1999 | 103 | 0.040 |
Why?
|
| Boron Compounds | 1 | 2020 | 196 | 0.040 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2018 | 23 | 0.040 |
Why?
|
| Gene Products, tat | 1 | 1998 | 111 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2013 | 1951 | 0.040 |
Why?
|
| Methylation | 1 | 2021 | 1078 | 0.040 |
Why?
|
| Chemokine CCL3 | 2 | 2008 | 85 | 0.040 |
Why?
|
| Proteomics | 2 | 2023 | 3912 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 616 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2332 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 498 | 0.040 |
Why?
|
| Aging | 5 | 2021 | 8744 | 0.040 |
Why?
|
| Biopsy | 3 | 2019 | 6793 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2024 | 24315 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2023 | 781 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2013 | 1968 | 0.040 |
Why?
|
| Oncogene Proteins v-fos | 1 | 2017 | 15 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 572 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1998 | 158 | 0.040 |
Why?
|
| Neomycin | 1 | 1997 | 94 | 0.040 |
Why?
|
| Zalcitabine | 1 | 1997 | 43 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 353 | 0.040 |
Why?
|
| Ubiquitins | 1 | 1999 | 366 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 1081 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 1169 | 0.040 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2017 | 83 | 0.040 |
Why?
|
| Acid Phosphatase | 2 | 2007 | 141 | 0.040 |
Why?
|
| Phenanthrolines | 1 | 2017 | 49 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 1627 | 0.040 |
Why?
|
| Ribavirin | 1 | 1999 | 395 | 0.040 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2008 | 103 | 0.040 |
Why?
|
| Isoenzymes | 3 | 2007 | 1688 | 0.040 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 1110 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2018 | 223 | 0.040 |
Why?
|
| Bone Marrow Examination | 2 | 2012 | 154 | 0.040 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2017 | 41 | 0.040 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2017 | 31 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 10399 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2018 | 271 | 0.040 |
Why?
|
| Stomatitis | 1 | 2000 | 271 | 0.040 |
Why?
|
| Blood Cells | 1 | 1999 | 309 | 0.040 |
Why?
|
| Skin | 1 | 2011 | 4503 | 0.040 |
Why?
|
| International Cooperation | 2 | 2014 | 1436 | 0.030 |
Why?
|
| Moloney murine leukemia virus | 1 | 1997 | 110 | 0.030 |
Why?
|
| Radiography | 1 | 2008 | 6983 | 0.030 |
Why?
|
| Nucleosides | 1 | 1997 | 130 | 0.030 |
Why?
|
| Retroviridae | 1 | 1999 | 846 | 0.030 |
Why?
|
| Mitochondrial Diseases | 1 | 2020 | 344 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 1999 | 825 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2018 | 264 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 492 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 998 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 2007 | 186 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2009 | 1134 | 0.030 |
Why?
|
| CpG Islands | 1 | 2021 | 1208 | 0.030 |
Why?
|
| COS Cells | 1 | 1998 | 1135 | 0.030 |
Why?
|
| Acyclovir | 1 | 1997 | 267 | 0.030 |
Why?
|
| Glycine | 1 | 2020 | 672 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2001 | 930 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1999 | 419 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 985 | 0.030 |
Why?
|
| Ploidies | 1 | 2017 | 287 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2862 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2007 | 294 | 0.030 |
Why?
|
| Leukocyte Transfusion | 1 | 1996 | 56 | 0.030 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2015 | 38 | 0.030 |
Why?
|
| Graft vs Host Reaction | 1 | 1996 | 99 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 1622 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 716 | 0.030 |
Why?
|
| Epigenomics | 1 | 2021 | 960 | 0.030 |
Why?
|
| Luminescent Proteins | 3 | 2003 | 838 | 0.030 |
Why?
|
| Homeodomain Proteins | 3 | 2013 | 2429 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 105 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2017 | 359 | 0.030 |
Why?
|
| Biological Products | 1 | 2024 | 948 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 381 | 0.030 |
Why?
|
| Receptors, KIR | 1 | 2015 | 114 | 0.030 |
Why?
|
| Multivariate Analysis | 4 | 2020 | 12077 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2018 | 622 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 44 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1999 | 365 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2015 | 143 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1997 | 830 | 0.030 |
Why?
|
| Rats, Inbred ACI | 1 | 1994 | 34 | 0.030 |
Why?
|
| Nimodipine | 1 | 2014 | 56 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2001 | 1171 | 0.030 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 783 | 0.030 |
Why?
|
| Base Composition | 1 | 2014 | 291 | 0.030 |
Why?
|
| Amyloidosis | 2 | 2003 | 878 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 802 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 1997 | 564 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 1805 | 0.030 |
Why?
|
| Hypertension | 1 | 2014 | 8616 | 0.030 |
Why?
|
| Oximes | 1 | 2015 | 303 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2014 | 2923 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2011 | 879 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1993 | 5432 | 0.030 |
Why?
|
| Risk | 2 | 2017 | 9613 | 0.030 |
Why?
|
| Thymidine | 1 | 1994 | 297 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 1997 | 301 | 0.030 |
Why?
|
| Lymphocyte Depletion | 2 | 2012 | 605 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 1398 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 1997 | 693 | 0.030 |
Why?
|
| Piracetam | 1 | 2014 | 88 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 606 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2020 | 1138 | 0.030 |
Why?
|
| Tritium | 1 | 1994 | 707 | 0.030 |
Why?
|
| France | 1 | 2015 | 497 | 0.030 |
Why?
|
| Myeloablative Agonists | 2 | 2007 | 210 | 0.030 |
Why?
|
| Phase Transition | 1 | 2013 | 70 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2015 | 6340 | 0.030 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2013 | 17 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 347 | 0.030 |
Why?
|
| Actins | 2 | 2015 | 2064 | 0.030 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2014 | 199 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1997 | 805 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2020 | 9669 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2013 | 185 | 0.030 |
Why?
|
| Vidarabine | 1 | 2014 | 337 | 0.030 |
Why?
|
| Nootropic Agents | 1 | 2014 | 159 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2019 | 2232 | 0.030 |
Why?
|
| Paracrine Communication | 2 | 2006 | 278 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2012 | 91 | 0.030 |
Why?
|
| Solutions | 1 | 2013 | 409 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 1999 | 13586 | 0.030 |
Why?
|
| Fibronectins | 2 | 2009 | 722 | 0.030 |
Why?
|
| Densitometry | 1 | 2012 | 151 | 0.030 |
Why?
|
| Buffers | 1 | 2012 | 143 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 1155 | 0.030 |
Why?
|
| Reference Values | 2 | 2014 | 4938 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 12543 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2013 | 433 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 2 | 2005 | 212 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14488 | 0.020 |
Why?
|
| Fever | 1 | 2000 | 1614 | 0.020 |
Why?
|
| Antimetabolites | 1 | 2012 | 128 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2005 | 384 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2013 | 279 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2013 | 204 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2012 | 249 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 14783 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 371 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 960 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 1998 | 3772 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2012 | 147 | 0.020 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2014 | 309 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 379 | 0.020 |
Why?
|
| Crystallization | 1 | 2012 | 520 | 0.020 |
Why?
|
| Leucine | 1 | 2013 | 547 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 4249 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2012 | 1057 | 0.020 |
Why?
|
| Cell Separation | 1 | 1997 | 1728 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 125 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2012 | 383 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 609 | 0.020 |
Why?
|
| Proline | 1 | 2013 | 455 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 4415 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 1206 | 0.020 |
Why?
|
| Drosophila | 1 | 1998 | 1513 | 0.020 |
Why?
|
| Vinblastine | 1 | 1992 | 487 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2014 | 914 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2011 | 159 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 26379 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 661 | 0.020 |
Why?
|
| Virion | 1 | 1993 | 428 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1083 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 580 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1993 | 410 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 457 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2015 | 12465 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 341 | 0.020 |
Why?
|
| HIV-1 | 2 | 1998 | 6961 | 0.020 |
Why?
|
| Androstadienes | 1 | 2012 | 348 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2744 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 472 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2013 | 444 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 399 | 0.020 |
Why?
|
| DNA Footprinting | 2 | 2000 | 97 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2010 | 294 | 0.020 |
Why?
|
| Subtraction Technique | 2 | 2003 | 517 | 0.020 |
Why?
|
| Caregivers | 1 | 2022 | 2302 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 806 | 0.020 |
Why?
|
| Forecasting | 2 | 2012 | 2945 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 239 | 0.020 |
Why?
|
| Linear Models | 1 | 2020 | 5884 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1994 | 2300 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 1990 | 188 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2010 | 144 | 0.020 |
Why?
|
| Immune System | 1 | 2015 | 799 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3216 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 424 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2012 | 912 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2009 | 32 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 178 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 190 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 1990 | 310 | 0.020 |
Why?
|
| Data Mining | 1 | 2014 | 563 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 251 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1990 | 339 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 1216 | 0.020 |
Why?
|
| Lung | 1 | 2008 | 10099 | 0.020 |
Why?
|
| Pedigree | 1 | 2017 | 4539 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 4912 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2009 | 53 | 0.020 |
Why?
|
| Protein Isoforms | 2 | 2006 | 1715 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
| Diterpenes | 1 | 1990 | 169 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2009 | 148 | 0.020 |
Why?
|
| Genome, Viral | 1 | 1993 | 674 | 0.020 |
Why?
|
| Urochordata | 1 | 2008 | 19 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 253 | 0.020 |
Why?
|
| Integrin alpha4beta1 | 1 | 2009 | 119 | 0.020 |
Why?
|
| Periodontal Pocket | 1 | 2009 | 174 | 0.020 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2008 | 5 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 389 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2008 | 65 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 330 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1999 | 1944 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 315 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 3740 | 0.020 |
Why?
|
| Virus Replication | 1 | 1996 | 2458 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 150 | 0.020 |
Why?
|
| Research Design | 1 | 2024 | 6211 | 0.020 |
Why?
|
| Pneumonia | 1 | 2000 | 2163 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 705 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 2396 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 2007 | 186 | 0.020 |
Why?
|
| Chemokines | 1 | 2012 | 963 | 0.020 |
Why?
|
| Granulocytes | 2 | 2001 | 551 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 127 | 0.020 |
Why?
|
| Seawater | 1 | 2008 | 126 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2008 | 75 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 122 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 179 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2015 | 1346 | 0.020 |
Why?
|
| Dromaiidae | 1 | 2007 | 7 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 229 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2009 | 3655 | 0.020 |
Why?
|
| Cathepsins | 1 | 2008 | 243 | 0.020 |
Why?
|
| Albumins | 1 | 2010 | 577 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 830 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 2735 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 2007 | 71 | 0.020 |
Why?
|
| Brain | 1 | 2014 | 27360 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 1567 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1120 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2002 | 662 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 1994 | 2916 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2016 | 2629 | 0.020 |
Why?
|
| Thrombocytosis | 1 | 2007 | 88 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2008 | 297 | 0.020 |
Why?
|
| Morpholines | 1 | 2010 | 584 | 0.020 |
Why?
|
| Temperature | 1 | 2013 | 2234 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 321 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 200 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1194 | 0.020 |
Why?
|
| Iron | 1 | 2015 | 1813 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 1162 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 600 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3187 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 3706 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 1407 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2006 | 75 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2022 | 4530 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1502 | 0.020 |
Why?
|
| Acute Disease | 1 | 1997 | 7243 | 0.020 |
Why?
|
| Family | 1 | 2017 | 3209 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 1419 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2008 | 391 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2007 | 251 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 582 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 1530 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2008 | 393 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2006 | 152 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15454 | 0.020 |
Why?
|
| Sepsis | 1 | 2000 | 2608 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 905 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2006 | 106 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2006 | 301 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 4427 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 213 | 0.020 |
Why?
|
| Somatomedins | 1 | 2006 | 179 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3239 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2001 | 1609 | 0.020 |
Why?
|
| Critical Illness | 1 | 2018 | 2756 | 0.020 |
Why?
|
| raf Kinases | 1 | 2005 | 117 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 15948 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 60 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2005 | 1536 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2005 | 342 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2219 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 361 | 0.020 |
Why?
|
| G2 Phase | 1 | 2005 | 134 | 0.010 |
Why?
|
| Patient Selection | 1 | 2017 | 4260 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4282 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
| Breast Neoplasms | 4 | 2011 | 21206 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 829 | 0.010 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2004 | 59 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2011 | 2089 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2029 | 0.010 |
Why?
|
| Contactins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 612 | 0.010 |
Why?
|
| Phosphoric Acids | 1 | 2003 | 19 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2014 | 1923 | 0.010 |
Why?
|
| Caspase 7 | 1 | 2003 | 51 | 0.010 |
Why?
|
| Lasers | 1 | 2008 | 952 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 611 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2007 | 1151 | 0.010 |
Why?
|
| Graft vs Host Disease | 3 | 2003 | 3049 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2004 | 194 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 173 | 0.010 |
Why?
|
| Liver | 1 | 1999 | 7577 | 0.010 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2003 | 105 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1133 | 0.010 |
Why?
|
| Health | 1 | 2006 | 398 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2005 | 430 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2003 | 92 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2013 | 5403 | 0.010 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2003 | 67 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 2003 | 78 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3858 | 0.010 |
Why?
|
| Anthracenes | 1 | 2003 | 83 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 1667 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 2004 | 164 | 0.010 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 118 | 0.010 |
Why?
|
| Physician's Role | 1 | 2010 | 925 | 0.010 |
Why?
|
| Emotions | 1 | 2015 | 2767 | 0.010 |
Why?
|
| Metaphase | 1 | 2003 | 143 | 0.010 |
Why?
|
| Rats | 2 | 2001 | 23760 | 0.010 |
Why?
|
| Kidney Diseases | 2 | 2007 | 2100 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 8230 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2003 | 206 | 0.010 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2002 | 111 | 0.010 |
Why?
|
| Phosphoserine | 1 | 2002 | 204 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2005 | 504 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2002 | 148 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 244 | 0.010 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2002 | 27 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2002 | 166 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 505 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2011 | 2418 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2002 | 94 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 102 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2002 | 118 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3390 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2002 | 70 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 455 | 0.010 |
Why?
|
| Macrophages | 1 | 1997 | 5799 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 370 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2003 | 252 | 0.010 |
Why?
|
| Palliative Care | 1 | 1997 | 3643 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2002 | 324 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2005 | 627 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 1328 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1737 | 0.010 |
Why?
|
| Splenectomy | 1 | 2003 | 392 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 195 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 3044 | 0.010 |
Why?
|
| Siblings | 1 | 2005 | 828 | 0.010 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2000 | 19 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2001 | 260 | 0.010 |
Why?
|
| Fluorescence | 1 | 2003 | 756 | 0.010 |
Why?
|
| Models, Animal | 1 | 2007 | 2120 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2013 | 2062 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 451 | 0.010 |
Why?
|
| Proteinuria | 1 | 2004 | 611 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 1616 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2002 | 304 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 2931 | 0.010 |
Why?
|
| Mental Health | 1 | 2015 | 3275 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 565 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2003 | 738 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 855 | 0.010 |
Why?
|
| Bence Jones Protein | 1 | 1999 | 19 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2002 | 457 | 0.010 |
Why?
|
| Rhodopsin | 1 | 2000 | 198 | 0.010 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2000 | 116 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2002 | 309 | 0.010 |
Why?
|
| Cytosol | 1 | 2003 | 887 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2002 | 611 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 2001 | 5315 | 0.010 |
Why?
|
| Globins | 1 | 2000 | 405 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 1999 | 44 | 0.010 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1883 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 1999 | 69 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 717 | 0.010 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 1999 | 91 | 0.010 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2002 | 296 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2002 | 594 | 0.010 |
Why?
|
| Serine | 1 | 2003 | 831 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2002 | 560 | 0.010 |
Why?
|
| Back Pain | 1 | 2003 | 548 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1999 | 150 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2003 | 1393 | 0.010 |
Why?
|
| Cyclins | 1 | 2001 | 606 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 2004 | 0.010 |
Why?
|
| Protein Folding | 1 | 2002 | 871 | 0.010 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 1998 | 39 | 0.010 |
Why?
|
| Estrogens | 1 | 2005 | 1536 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 1998 | 72 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 762 | 0.010 |
Why?
|
| Paxillin | 1 | 1998 | 86 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2002 | 725 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2001 | 640 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 363 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 1951 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1999 | 287 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2000 | 577 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1998 | 120 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2002 | 832 | 0.010 |
Why?
|
| Adolescent | 2 | 2024 | 89169 | 0.010 |
Why?
|
| Androgens | 1 | 2005 | 1281 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 787 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 1765 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 2479 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 2000 | 321 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3533 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 1369 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 887 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1999 | 269 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 1683 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2002 | 575 | 0.010 |
Why?
|
| KB Cells | 1 | 1996 | 13 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2000 | 792 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 1999 | 500 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 1323 | 0.010 |
Why?
|
| Thiotepa | 1 | 1996 | 66 | 0.010 |
Why?
|
| Bone Density | 1 | 2009 | 3573 | 0.010 |
Why?
|
| Vincristine | 1 | 1999 | 1040 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2000 | 842 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 3703 | 0.010 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2004 | 1613 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 1999 | 437 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 849 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 1542 | 0.010 |
Why?
|
| Antioxidants | 1 | 2003 | 1673 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 775 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1625 | 0.010 |
Why?
|
| Haplorhini | 1 | 1995 | 523 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1999 | 667 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 5792 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2005 | 2603 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1281 | 0.010 |
Why?
|
| Luciferases | 1 | 1996 | 713 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 686 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1995 | 1550 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 2914 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 6974 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 2094 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 4620 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2001 | 1791 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 753 | 0.010 |
Why?
|
| Reoperation | 1 | 2001 | 4329 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1993 | 11101 | 0.010 |
Why?
|
| Retina | 1 | 2000 | 2662 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2002 | 4492 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1999 | 2479 | 0.000 |
Why?
|
| Logistic Models | 1 | 2002 | 13290 | 0.000 |
Why?
|
| Ventricular Function, Left | 1 | 2000 | 3941 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1999 | 8741 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7477 | 0.000 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1993 | 1164 | 0.000 |
Why?
|
| Kidney | 1 | 1995 | 7064 | 0.000 |
Why?
|
| Child | 1 | 1999 | 80917 | 0.000 |
Why?
|